Healthcare-associated, Community-acquired and Hospital-acquired Bacteraemic Urinary Tract Infections in Hospitalized Patients: a Prospective Multicentre Cohort Study in the Era of Antimicrobial Resistance
Overview
Authors
Affiliations
The clinical and microbiological characteristics of community-onset healthcare-associated (HCA) bacteraemia of urinary source are not well defined. We conducted a prospective cohort study at eight tertiary-care hospitals in Spain, from October 2010 to June 2011. All consecutive adult patients hospitalized with bacteraemic urinary tract infection (BUTI) were included. HCA-BUTI episodes were compared with community-acquired (CA) and hospital-acquired (HA) BUTI. A logistic regression analysis was performed to identify 30-day mortality risk factors. We included 667 episodes of BUTI (246 HCA, 279 CA and 142 HA). Differences between HCA-BUTI and CA-BUTI were female gender (40% vs 69%, p <0.001), McCabe score II-III (48% vs 14%, p <0.001), Pitt score ≥2 (40% vs 31%, p 0.03), isolation of extended spectrum β-lactamase-producing Enterobacteriaciae (13% vs 5%, p <0.001), median hospital stay (9 vs 7 days, p 0.03), inappropriate empirical antimicrobial therapy (21% vs 13%, p 0.02) and mortality (11.4% vs 3.9%, p 0.001). Pseudomonas aeruginosa was more frequently isolated in HA-BUTI (16%) than in HCA-BUTI (4%, p <0.001). Independent factors for mortality were age (OR 1.04; 95% CI 1.01-1.07), McCabe score II-III (OR 3.2; 95% CI 1.8-5.5), Pitt score ≥2 (OR 3.2 (1.8-5.5) and HA-BUTI OR 3.4 (1.2-9.0)). Patients with HCA-BUTI are a specific group with significant clinical and microbiological differences from patients with CA-BUTI, and some similarities with patients with HA-BUTI. Mortality was associated with patient condition, the severity of infection and hospital acquisition.
Neary M, Catillon M, Ahmad N, Gauthier-Loiselle M, Geurtsen J, Qu A Infect Dis Ther. 2025; .
PMID: 39918690 DOI: 10.1007/s40121-024-01096-w.
Wu W, Xiao S, Han L, Wu Q Microbiol Spectr. 2024; 13(1):e0121724.
PMID: 39612477 PMC: 11705914. DOI: 10.1128/spectrum.01217-24.
Maldonado-Barragan A, Mshana S, Keenan K, Ke X, Gillespie S, Stelling J JAC Antimicrob Resist. 2024; 6(1):dlae019.
PMID: 38372000 PMC: 10873138. DOI: 10.1093/jacamr/dlae019.
Godijk N, McDonald S, Altorf-van der Kuil W, Schoffelen A, Franz E, Bootsma M BMJ Open. 2023; 13(12):e064335.
PMID: 38110375 DOI: 10.1136/bmjopen-2022-064335.
Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury A, Kalu N, Gauthier-Loiselle M BMC Infect Dis. 2023; 23(1):550.
PMID: 37608247 PMC: 10464165. DOI: 10.1186/s12879-023-08479-3.